Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 13, 2026
UiPath (PATH) Q2 Fiscal 2027 Earnings Preview: Key Metrics Investors Are Watching

UiPath (PATH) Q2 Fiscal 2027 Earnings Preview: Key Metrics Investors Are Watching

Key Takeaways

  • UiPath (PATH) is scheduled to report second quarter fiscal 2027 results after the market closes on Thursday, September 3, 2026.
  • Wall Street consensus projects adjusted (non-GAAP) earnings per share (EPS) of about $0.15, roughly flat with $0.15 in the year-ago quarter.
  • Consensus revenue estimates sit near $397.6 million, up about 10% from $362.0 million in the second quarter of fiscal 2026.
  • Management has guided second quarter revenue to $395–$400 million, with annual recurring revenue (ARR) of $1.929–$1.934 billion and non-GAAP operating income of approximately $75 million.
  • Investors will focus on ARR, net new ARR, and dollar-based net retention after first quarter ARR rose 12% year over year to $1.901 billion.
  • AI adoption remains a central theme: 16 of UiPath's top 20 deals in the first quarter included AI components.

Why This Report Matters Right Now

This earnings update comes at an important juncture for UiPath (PATH), a leader in business orchestration and enterprise automation. The company finished its fiscal first quarter with revenue up 17% year over year, its first GAAP operating profit, and increasing AI-related deal activity. Shares pulled back afterward, however, as adjusted EPS fell short of some estimates despite the revenue beat. The second-quarter fiscal 2027 release will help clarify whether enterprise demand for automation and agentic AI is translating into sustained, accelerating recurring revenue growth. To get a broader view of how PATH compares with peers, I ran a quick check through Tickeron’s AI Screener.

What Analysts Expect

UiPath will report results for its second quarter of fiscal 2027, which ended July 31, 2026, after the market closes on September 3, 2026. Analysts expect adjusted EPS of approximately $0.15, essentially unchanged from the year-ago quarter. Consensus revenue estimates are around $397.6 million, representing growth of roughly 10% from $362.0 million in the prior-year period.

The company’s own guidance calls for second-quarter revenue of $395 million to $400 million, ARR of $1.929 billion to $1.934 billion, and non-GAAP operating income of about $75 million. For context, UiPath reported first-quarter fiscal 2027 revenue of $418.38 million, up 17.3% year over year, with adjusted EPS of $0.15. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Key metrics to watch include net new ARR, dollar-based net retention, customer counts at higher ARR thresholds, and whether AI-related products continue to expand within existing accounts.

Market Sentiment Heading Into the Print

Sentiment around UiPath remains measured. After the first-quarter fiscal 2027 release in May, PATH shares slipped in after-hours trading as a modest adjusted EPS shortfall overshadowed a revenue beat and solid full-year guidance. Since then, the stock has continued to face scrutiny as investors weigh slower ARR growth against improving profitability and the company’s AI narrative. Key risk factors include enterprise budget constraints, foreign exchange headwinds, and competition in automation and AI software. A better-than-expected ARR figure or commentary on AI-driven deal expansion could shape the market’s reaction.

What to Watch in the Outlook

For the full fiscal year 2027, UiPath expects revenue of $1.776 billion to $1.781 billion, ARR of $2.058 billion to $2.063 billion, and non-GAAP operating income of approximately $430 million. The second-quarter update will show whether management remains on track toward those targets.

Investors should monitor several signals. First, net new ARR and dollar-based net retention will indicate whether existing customers are expanding their usage. Second, commentary on AI-related products, including coding agents and Maestro Case, may provide insight into how new offerings are contributing to deal sizes. Third, non-GAAP operating margin will reveal how efficiently the company is scaling while investing in growth. Finally, any updates on foreign exchange effects, public sector demand, and enterprise spending trends will help frame the outlook for the remainder of the fiscal year.

My Take on Using Tickeron’s AI Screener

When I’m preparing for reports like this one, I often use Tickeron’s AI Screener to quickly filter automation and AI-related names by fundamentals, technical patterns, and performance metrics. It helps me build focused watchlists and compare emerging opportunities without spending hours on manual work. The tool has become a regular part of my process for identifying trade ideas and staying on top of sector trends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PATH

PATH in upward trend: price rose above 50-day moving average on July 27, 2026

PATH moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on PATH as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PATH just turned positive on July 29, 2026. Looking at past instances where PATH's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PATH advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 157 cases where PATH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PATH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PATH broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PATH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.281) is normal, around the industry mean (24.057). P/E Ratio (26.200) is within average values for comparable stocks, (74.273). Projected Growth (PEG Ratio) (0.565) is also within normal values, averaging (1.911). PATH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (5.074) is also within normal values, averaging (134.061).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PATH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Block Inc (NYSE:XYZ), Twilio (NYSE:TWLO), NetApp (NASDAQ:NTAP), MongoDB (NASDAQ:MDB), Zscaler (NASDAQ:ZS), Okta (NASDAQ:OKTA).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.26B. The market cap for tickers in the group ranges from 48.8K to 3.74T. MSFT holds the highest valuation in this group at 3.74T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 25%. AIFA experienced the highest price growth at 94%, while GYGY experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -28%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was -65%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 72
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 91
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
PATH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ComputerCommunications

Profile
Details
Industry
N/A
Address
One Vanderbilt Avenue
Phone
+1 844 432-0455
Employees
3024
Web
https://www.uipath.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.